Skip to main content
. 2009 Jul;58(7):1471–1478. doi: 10.2337/db09-0119

TABLE 3.

Angit-angiogenic therapy in diabetic nephropathy

Anti-VEGF antibody
 SU5416
 Angiostatin
 Endostatin
 Tumstatin
 NM-3
 PEDF
Blocking VEGF
 Pan-VEGFR kinase inhibitor
 Proteolytic fragment of plasminogen
 NC1 domain of type 18 collagen
 NC domain of the α3 chain of type 4 collagen
 2-(8-hydroxy-6-methoxy-1-oxo-1H-2-benxopyran-3-yl) propionic acid
 Pigment epithelium-derived factor
STZ Wister rat* db/db mouse* GK rat* db/db mouse STZ Brown Norway rat STZ-C57BL6 mouse* STZ-C57BL6 mouse* db/db mouse* STZ Brown Norway rat
Age or weight 250–280 g 8 weeks 8 weeks 8 weeks 8 weeks 7–8 weeks 7–8 weeks 7–8 weeks 8 weeks
Treatment duration ≤6 weeks 60 days 6 weeks 8 weeks 2–3 weeks 4 weeks 2–3 weeks 8 weeks 3 weeks
Increase in CD31(+) endothelial cell in glomeruli NE NE NE NE NE Blocked Blocked Blocked NE
Renal hypertrophy NE Blocked NE NE NE Blocked Blocked Not blocked NE
Glomerular hypertrophy Blocked Blocked No effect NE Blocked Blocked Blocked Blocked NE
Mesangial expansion NE Tended to be lowered NE Blocked NE Blocked Blocked Blocked NE
Glomerular basement membrane thickening NE Blocked NE Blocked NE NE NE NE NE
Hyperfiltration Blocked Blocked No effect NE NE Blocked Blocked Blocked NE
Urinary albumin Decreased Decreased No effect Decreased Decreased Decreased Decreased Decreased Decreased
Podocyte injury or Nephrin expression NE NE NE Improved NE Recovered (Nephrin expression) Recovered (Nephrin expression) Recovered (Nephrin expression) NE
Macrophage infiltration NE NE NE NE NE Blocked Blocked Blocked NE
VEGF expression NE NE NE NE Decreased Decreased Decreased Decreased NE
TGF-β1 expression NE NE NE NE Decreased Decreased NE Decreased Decreased
Reference 49 50 51 52 64 14 16 13 74, 75

NE, not examined; STZ, streptocotocin.

*Female.